Mikhail Blagosklonny is on the forefront of aging research and is one of the few MD’s out there that can boast a peer-reviewed journal that he created. Oncotarget is its name, with articles from all over the world and free access through the internet. The journal studies all aspects of oncology and has put Blagosklonny on the map for its unique perspectives and influential articles.
Mikhail Blagosklonny started out humbly in Soviet Russia, where he was raised, and quickly became a name to know in the United States when he eventually moved. He received his MD in internal medicine and phD in experimental medicine from First Pavlov State Medical University of St. Petersburg. He is now a professor of oncology at Roswell Park Cancer Institute in 2009; before then, he was a senior scientist at Ordway Research Institute in Albany, NY, until 2009.
Visit classroomvoices.org to read more about Mikhail.
He is editor-in-chief of several publications, including Aging and Cell Cycle, as well as his journal Octotarget. His studies on the role of TOR, signaling in aging and cancer is well known in the medical community, receiving many accolades as a potential key to unlocking the anti-aging process. Blagosklonny is a big proponent of rapamycin, a popular cancer drug that he sees as a vital medicine that could be used to arrest the aging process.
He currently lives in New York, New York and focuses his time on his journal and work in oncology. He has published over 270 papers in peer reviewed journals and has been cited over 25,000 times, making him quite a name in the medical science community. His further work in the anti-aging properties and rapamycin puts him on the forefront of anti-aging research: an area that is quite popular and trending in modern times. Not only is he interested in reversing the aging of cells, he is interested in the underlying mechanisms of aging and the mechanics of how the process is received by cells and spreads throughout the body. Visit ResearchGate.Net to learn more about Mikhail’s latest work.